UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB APPROVAL
OMB Number: 3235-0145
Expires August 31, 1999
Estimated average burden
hours per response .. 14.90
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
BIO-REFERENCE LABORATORIES, INC.
(Name of Issuer)
Common Stock, par value $.01 par value
(Title of Class of Securities)
090576 60 2
(CUSIP Number)
Marc D. Grodman
481 Edward H. Ross Drive
Elmwood Park, New Jersey 07407
(201) 791-2600
(Name, Address and Telephone Number of Persona Authorized to
Receive Notices and Communications)
July 22, 1999
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss.240.13d-1(d), 24013d-1(f), check the following box.
___
Note: Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See ss.240.13d-7 for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Potential persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently
valid OMB control number.
<PAGE>
CUSIP NO. 090576 60 2
1. Names of Reporting Persons: Marc D. Grodman
I.R.S. Identification Nos. of above persons (entities only)
========================================================================
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
(b) X
3. SEC Use Only
========================================================================
4. Source of Funds (See Instructions) PF
------------------------------------------------------------------------
5. Check If Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d)
or 2 (c)
6. Citizenship or Place of Organization: United States
Number of 7. Sole Voting Power . . . . . . . . . . . 1,465,778(a)
Shares
Beneficially 8. Shared Voting Power . . . . . . . . . . 196,067(b)
Owned by
Each 9. Sole Dispositive Power. . . . . . . . . 1,465,778(a)
Reporting
Person 10. Shared Dispositive Power. . . . . . . . 196,067(b)
With
------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
1,661,845 shares (b)
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)
------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11) 20.5%
------------------------------------------------------------------------
14. Type of Reporting Person (see instructions) IN
------------------------------------------------------------------------
(a) Includes 549,678 shares issuable upon conversion of senior preferred stock
and 300,000 share issuable upon exercise of options.
(b) Includes 141,667 shares owned directly by Dr. Grodman's wife and 54,400
shares issuable upon conversion of senior preferred stock owned by Dr. Grodman's
wife. Dr. Grodman disclaims beneficial ownership of these shares.
<PAGE>
Marc D. Grodman
Amendment No. 4 to
Schedule 13D
re
Bio-Reference Laboratories, Inc.
Item 1. Security and Issuer
The issuer of the securities is Bio-Reference Laboratories, Inc. ("BRLI"), a New
Jersey corporation with principal offices at 481 Edward H. Ross Drive, Elmwood
Park, New Jersey 07407. The equity securities to which this statement related
are share of BRLI common stock, $.01 par value.
Item 2. Identity and Background
Dr. Grodman, whose principal business address is the same as BRLI, is a United
States citizen and is the president and chief executive officer of BRLI. During
the past five years, Dr. Grodman has not been convicted in a criminal proceeding
or been the subject of a judgement, decree or final order of nature described in
Item 2 to Schedule 13D..
Item 3. Source and Amount of Funds or Other Consideration
The Amendment related to open market purchases made by Dr. Grodman in July 1999
of an aggregate 140,000 shares of BRLI common stock for an aggregate of
approximately $138,500. Dr. Grodman used personal funds for these purchases.
Item 4. Purpose of Transaction
Dr. Grodman purchased the 140,000 shares for investment purposes. With the
exception of proposed transactions already publicly disclosed, Dr. Grodman has
no current plans involving BRLI which related to the items described in Item 4
of Schedule 13D (a) through (j).
Item 5. Interest in Securities of the Issuer
(a) BRLI has 7,222,910 shares of common stock issued and outstanding. As a
result of the purchases described herein, Dr. Grodman may be deemed the
beneficial owner of 1,661,845 shares comprising 20.5% of such common stock. This
amount includes 616,100 shares owned directly, 549,678 shares issuable upon
conversion of senior preferred stock and 300,000 shares issuable upon exercise
of options owned by Dr. Grodman, and 141,667 shares owned directly by Dr.
Grodman's wife and 54,400 shares issuable upon conversion of senior preferred
stock owned by Dr. Grodman's wife. Dr. Grodman disclaims beneficial ownership of
these 196,067 shares beneficially owned by his wife.
(b) At the present time, Dr. Grodman has the sole power to vote the 616,100
shares of common stock and 549,678 shares of senior preferred stock owned by him
and the sole power to dispose of or to direct the disposition of such shares as
well as the 300,000 shares issuable upon the exercise of options owned by him.
<PAGE>
(c) The following table details the transactions in BRLI common stock during the
past 6 days by Dr. Grodman. All of such transactions were open market purchases.
Date Quantity (in shares) Price
July 15, 1999 5,000 29/32
July 15, 1999 10,000 15/16
July 15, 1999 11,000 31/32
July 15, 1999 11,100 1
July 19, 1999 1,275 15/15
July 19, 1999 5,100 [ ]/16
July 19, 1999 5,500 31/32
July 19, 1999 6,800 1
July 20, 1999 16,000 1
July 21, 1999 7,200 31/32
July 21, 1999 8,500 1
July 22, 1999 800 1
July 22, 1999 3,400 31/32
July 22, 1999 13,000 29/32
July 22, 1999 34,200 1
July 23, 1999 1,000 15/16
July 26, 1999 125 31/32
----------
140,000
(d) Inapplicable.
(e) Inapplicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer
Inapplicable.
Item 7. Material to be filed as Exhibits
Inapplicable.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Date: July 27, 1999 /s/ Marc D. Grodman
-------------------
Marc D. Grodman
